292 related articles for article (PubMed ID: 26800393)
21. First-in-Human Study of PF-05212384 (PKI-587), a Small-Molecule, Intravenous, Dual Inhibitor of PI3K and mTOR in Patients with Advanced Cancer.
Shapiro GI; Bell-McGuinn KM; Molina JR; Bendell J; Spicer J; Kwak EL; Pandya SS; Millham R; Borzillo G; Pierce KJ; Han L; Houk BE; Gallo JD; Alsina M; Braña I; Tabernero J
Clin Cancer Res; 2015 Apr; 21(8):1888-95. PubMed ID: 25652454
[TBL] [Abstract][Full Text] [Related]
22. Clinical and translational studies of a phase II trial of the novel oral Akt inhibitor perifosine in relapsed or relapsed/refractory Waldenstrom's macroglobulinemia.
Ghobrial IM; Roccaro A; Hong F; Weller E; Rubin N; Leduc R; Rourke M; Chuma S; Sacco A; Jia X; Azab F; Azab AK; Rodig S; Warren D; Harris B; Varticovski L; Sportelli P; Leleu X; Anderson KC; Richardson PG
Clin Cancer Res; 2010 Feb; 16(3):1033-41. PubMed ID: 20103671
[TBL] [Abstract][Full Text] [Related]
23. Phase I dose-escalation trial of the oral investigational Hedgehog signaling pathway inhibitor TAK-441 in patients with advanced solid tumors.
Goldman J; Eckhardt SG; Borad MJ; Curtis KK; Hidalgo M; Calvo E; Ryan DP; Wirth LJ; Parikh A; Partyka J; Faessel H; Gangolli E; Stewart S; Rosen LS; Bowles DW
Clin Cancer Res; 2015 Mar; 21(5):1002-9. PubMed ID: 25501576
[TBL] [Abstract][Full Text] [Related]
24. Treatment of relapsed and refractory Waldenstrom Macroglobulinemia.
Amaador K; Kersten MJ; Minnema MC; Vos JMI
Leuk Lymphoma; 2023 Jan; 64(1):30-41. PubMed ID: 36282673
[TBL] [Abstract][Full Text] [Related]
25. Treatment of relapsed or refractory Waldenström's macroglobulinemia with bortezomib.
Dimopoulos MA; Anagnostopoulos A; Kyrtsonis MC; Castritis E; Bitsaktsis A; Pangalis GA
Haematologica; 2005 Dec; 90(12):1655-8. PubMed ID: 16330439
[TBL] [Abstract][Full Text] [Related]
26. A phase II study to assess the safety and efficacy of the dual mTORC1/2 inhibitor vistusertib in relapsed, refractory DLBCL.
Eyre TA; Hildyard C; Hamblin A; Ali AS; Houlton A; Hopkins L; Royston D; Linton KM; Pettitt A; Rule S; Cwynarski K; Barrington SF; Warbey V; Wrench D; Barrans S; Hirst CS; Panchal A; Roudier MP; Harrington EA; Davies A; Collins GP
Hematol Oncol; 2019 Oct; 37(4):352-359. PubMed ID: 31385336
[TBL] [Abstract][Full Text] [Related]
27. A Phase I Dose-Escalation Study of Clofarabine in Patients with Relapsed or Refractory Low-Grade or Intermediate-Grade B-Cell or T-Cell Lymphoma.
Foss FM; Parker T
Oncologist; 2018 Apr; 23(4):397-e30. PubMed ID: 29438091
[TBL] [Abstract][Full Text] [Related]
28. A First-in-Human Phase 1 Study of LY3023414, an Oral PI3K/mTOR Dual Inhibitor, in Patients with Advanced Cancer.
Bendell JC; Varghese AM; Hyman DM; Bauer TM; Pant S; Callies S; Lin J; Martinez R; Wickremsinhe E; Fink A; Wacheck V; Moore KN
Clin Cancer Res; 2018 Jul; 24(14):3253-3262. PubMed ID: 29636360
[No Abstract] [Full Text] [Related]
29. Utility of mTOR inhibition in hematologic malignancies.
Younes A; Samad N
Oncologist; 2011; 16(6):730-41. PubMed ID: 21632450
[TBL] [Abstract][Full Text] [Related]
30. Lenalidomide is safe and active in Waldenström macroglobulinemia.
Fouquet G; Guidez S; Petillon MO; Louni C; Ohyba B; Dib M; Poulain S; Herbaux C; Martin A; Thielemans B; Brice P; Choquet S; Bakala J; Bories C; Demarquette H; Nudel M; Tournilhac O; Arnulf B; LeGouill S; Morel P; Banos A; Karlin L; Salles G; Leblond V; Leleu X
Am J Hematol; 2015 Nov; 90(11):1055-9. PubMed ID: 26284823
[TBL] [Abstract][Full Text] [Related]
31. A Phase 1 Study of Sapanisertib (TAK-228) in East Asian Patients with Advanced Nonhematological Malignancies.
Shimizu T; Kuboki Y; Lin CC; Yonemori K; Yanai T; Faller DV; Dobler L; Gupta N; Sedarati F; Kim KP
Target Oncol; 2022 Jan; 17(1):15-24. PubMed ID: 34843044
[TBL] [Abstract][Full Text] [Related]
32. The Plk1 inhibitor BI 2536 in patients with refractory or relapsed non-Hodgkin lymphoma: a phase I, open-label, single dose-escalation study.
Vose JM; Friedberg JW; Waller EK; Cheson BD; Juvvigunta V; Fritsch H; Petit C; Munzert G; Younes A
Leuk Lymphoma; 2013 Apr; 54(4):708-13. PubMed ID: 22978685
[TBL] [Abstract][Full Text] [Related]
33. Mechanisms of activity of the TORC1 inhibitor everolimus in Waldenstrom macroglobulinemia.
Roccaro AM; Sacco A; Jia X; Banwait R; Maiso P; Azab F; Flores L; Manier S; Azab AK; Ghobrial IM
Clin Cancer Res; 2012 Dec; 18(24):6609-22. PubMed ID: 23048077
[TBL] [Abstract][Full Text] [Related]
34. A Phase Ib/II Study of Oprozomib in Patients with Advanced Multiple Myeloma and Waldenström Macroglobulinemia.
Ghobrial IM; Vij R; Siegel D; Badros A; Kaufman J; Raje N; Jakubowiak A; Savona MR; Obreja M; Berdeja JG
Clin Cancer Res; 2019 Aug; 25(16):4907-4916. PubMed ID: 31142508
[TBL] [Abstract][Full Text] [Related]
35. A phase I dose-escalation study of TAK-733, an investigational oral MEK inhibitor, in patients with advanced solid tumors.
Adjei AA; LoRusso P; Ribas A; Sosman JA; Pavlick A; Dy GK; Zhou X; Gangolli E; Kneissl M; Faucette S; Neuwirth R; Bózon V
Invest New Drugs; 2017 Feb; 35(1):47-58. PubMed ID: 27650277
[TBL] [Abstract][Full Text] [Related]
36. Phase I Study of Lysine-Specific Demethylase 1 Inhibitor, CC-90011, in Patients with Advanced Solid Tumors and Relapsed/Refractory Non-Hodgkin Lymphoma.
Hollebecque A; Salvagni S; Plummer R; Isambert N; Niccoli P; Capdevila J; Curigliano G; Moreno V; Martin-Romano P; Baudin E; Arias M; Mora S; de Alvaro J; Di Martino J; Parra-Palau JL; Sánchez-Pérez T; Aronchik I; Filvaroff EH; Lamba M; Nikolova Z; de Bono JS
Clin Cancer Res; 2021 Jan; 27(2):438-446. PubMed ID: 33046517
[TBL] [Abstract][Full Text] [Related]
37. Ibrutinib Efficacy, Safety, and Pharmacokinetics in Chinese Patients with Relapsed or Refractory Waldenström's Macroglobulinemia: A Multicenter, Single-Arm, Phase 4 Study.
Yi S; Cai Z; Hu Y; He A; Gao S; Li Q; Sha L; Zhang N; Ren Y; Gai X; Yang X; Qin R; Qiu L
Adv Ther; 2024 Feb; 41(2):672-685. PubMed ID: 38079089
[TBL] [Abstract][Full Text] [Related]
38. Otlertuzumab (TRU-016), an anti-CD37 monospecific ADAPTIR(™) therapeutic protein, for relapsed or refractory NHL patients.
Pagel JM; Spurgeon SE; Byrd JC; Awan FT; Flinn IW; Lanasa MC; Eisenfeld AJ; Stromatt SC; Gopal AK
Br J Haematol; 2015 Jan; 168(1):38-45. PubMed ID: 25146490
[TBL] [Abstract][Full Text] [Related]
39. Phase I study of OPB-51602, an oral inhibitor of signal transducer and activator of transcription 3, in patients with relapsed/refractory hematological malignancies.
Ogura M; Uchida T; Terui Y; Hayakawa F; Kobayashi Y; Taniwaki M; Takamatsu Y; Naoe T; Tobinai K; Munakata W; Yamauchi T; Kageyama A; Yuasa M; Motoyama M; Tsunoda T; Hatake K
Cancer Sci; 2015 Jul; 106(7):896-901. PubMed ID: 25912076
[TBL] [Abstract][Full Text] [Related]
40. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
Plosker GL; Figgitt DP
Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]